CN105901712A - Microemulsion for preventing constipation of diabetics and preparation method thereof - Google Patents
Microemulsion for preventing constipation of diabetics and preparation method thereof Download PDFInfo
- Publication number
- CN105901712A CN105901712A CN201610264495.8A CN201610264495A CN105901712A CN 105901712 A CN105901712 A CN 105901712A CN 201610264495 A CN201610264495 A CN 201610264495A CN 105901712 A CN105901712 A CN 105901712A
- Authority
- CN
- China
- Prior art keywords
- microemulsion
- constipation
- preservative
- distilled water
- span
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004530 micro-emulsion Substances 0.000 title claims abstract description 28
- 206010010774 Constipation Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000012153 distilled water Substances 0.000 claims abstract description 18
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 17
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 17
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 17
- 239000003755 preservative agent Substances 0.000 claims abstract description 17
- 230000002335 preservative effect Effects 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 17
- 239000010495 camellia oil Substances 0.000 claims abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 230000002378 acidificating effect Effects 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000013355 food flavoring agent Nutrition 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 7
- 235000010199 sorbic acid Nutrition 0.000 claims description 7
- 239000004334 sorbic acid Substances 0.000 claims description 7
- 229940075582 sorbic acid Drugs 0.000 claims description 7
- 238000013019 agitation Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004064 cosurfactant Substances 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 7
- 210000002784 stomach Anatomy 0.000 abstract description 6
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000005593 Camellia sinensis f parvifolia Nutrition 0.000 description 1
- 244000041840 Camellia sinensis f. parvifolia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- -1 medically Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a microemulsion for prevention constipation of diabetics and a preparation method thereof, and relates to the field of healthcare food. The microemulsion comprises: 20-30% of camellia oil, 30-40% of surfactant, 0.1-3.0% of fructo-oligose, 0.1-1.0% of stachyose, 0.01-0.05% of preservative, and 0.5-1.0% of acidulant, with the balance being glycerin and distilled water. The preparation method comprises steps of dissolving the fructo-oligose, the stachyose, the preservative and the acidulant into the distilled water, then uniformly mixing them with the glycerin, adding Tween-80 to obtain a clear transparent solution; mixing the camellia oil with Span-80 to obtain a yellow clear solution; adding the clear transparent solution into the yellow clear solution to obtain a clear orange-yellow microemulsion. Comparing to prior arts, the microemulsion for preventing constipation of diabetics does not contain sugar, so it is not only of a good effect, but also is free of toxin and side effects. With a good taste and an attractive appearance, the microemulsion for preventing constipation of diabetics is an ideal functional food for diabetics to coordinate intestines and stomach as well as prevent constipation.
Description
Technical field
The present invention relates to technical field of health care food, a kind of diabetes patient that is applicable to loosening bowel to relieve constipation prevents
Microemulsion of constipation and preparation method thereof.
Background technology
It is known that along with the sickness rate of the improvement of people living condition, living-pattern preservation, diabetes and complication
Day by day raising, diabetic gastrointestinal disease is the chronic complicating diseases that diabetes are common, and prevalence is 30%-76%, and constipation is
The most common symptom of diabetes gastrointestinal disease, accounts for 60%, and its pathogenesis is not fully understood, it may be possible to due to hyperglycemia
And Developmental and Metabolic Disorder, cause neural malnutrition, arrange gastrointestinal nerve damage.Western medicine there is no specific treatment method and hands at present
Section, conventional symptomatic treatment medicine: cisapride sheet, phenolphthalein tablets etc., but some patients have dizziness, distending pain in the head, drowsiness, tongue is numb,
Abdominal discomfort, arrhythmia etc. are reacted, it is impossible to tolerance, once have gynecomasty, galactorrhea, convulsive epilepsy, extrapyramidal system
Reaction and the Case report of frequent micturition, limit its clinical practice, and the health of the people in serious threat, under making quality of life comprehensively
Fall.
Constipation patient mainly can show as the situations such as defecation frequency reduces, feces amount reduces, feces is dry and hard, defecation is laborious,
Long-term constipation can induce mastopathy, degenerative brain disorder.
Oleum Camelliae is the distinctive woody oils and fats of China, its fatty acid composition and the best Vegetable oil lipoprotein Fructus Canarii albi generally acknowledged in the world
Oil phase seemingly, has the laudatory title of " east olive oil ", and containing several functions composition in Oleum Camelliae, its health care and medicinal efficacy the most just have
Record:
The Compendium of Material Medica of Li Shizhen (1518-1593 A.D.): " camellia oleosa seed, bitter cold perfume (or spice) poison, cure mainly breathe heavily cough, go disease dirt ... ".
" agricultural administration book " there is Camellia oil can treat hemorrhoid, move back damp and hot record.
Supplementary Amplifications of the Compendium of Materia Medica is said, Oleum Camelliae can intestine moistening, clearing stomach, detoxicating, killing bacteria.
" agriculture breath occupy diet spectrum " has " Oleum Camelliae is moisturized, heat clearing away, endogenous wind stopping and the clear profit head ".
Oleum Camelliae is praised by " occupying diet spectrum with breath " especially, " Oleum Camelliae cooking sumptuous courses at a meal, daily all suitable, cook food, pool occurs
Light, only this is the most clear for all oil, therefore all diseases are not avoided."
But Oleum Camelliae scent of, and greasy heavy, directly take and be difficult to obtain consumers in general's acceptance, add that it belongs to oily matter,
It is difficult to add thereto water-solubility function material.If imaging beverage based food can be done, both having had good functional, taste is all again
Good, the favor of consumer at different levels will be obtained.
Summary of the invention
Problem to be solved by this invention be to provide a kind of there is good the intestines and stomach coordinating effect be applicable to diabetes patient
Microemulsion of Constipation and preparation method thereof.
In order to solve above-mentioned technical problem, scheme of the present invention is:
It includes the raw material of following weight percents:
Camellia oil 20-30%, surfactant 30-40%, oligofructose 0.1-3.0%, stachyose 0.1-1.0%, preservative
The weight of 0.01-0.05%, acidic flavoring agent 0.5-1.0%, cosurfactant glycerol and distilled water surplus, glycerol and distilled water
Amount ratio is 30:70-60:40.
In technique scheme, more specifically scheme is it may also is that described surfactant is Span-80 and Tween-
80, the weight ratio of described Span-80 and Tween-80 is 3:7～5:5.
Further: described preservative is sorbic acid and potassium salt thereof.
The two of problem to be solved by this invention are to provide a kind of microemulsion making simply and making to be had well
The preparation method of the microemulsion being applicable to diabetes patient's Constipation of the intestines and stomach coordinating effect.
In order to solve above-mentioned technical problem, scheme of the present invention is:
Use the raw material of following percentage by weight:
Camellia oil 20-30%, surfactant 30-40%, oligofructose 0.1-3.0%, stachyose 0.1-1.0%, preservative
The weight of 0.01-0.05%, acidic flavoring agent 0.5-1.0%, cosurfactant glycerol and distilled water surplus, glycerol and distilled water
Amount ratio is 30:70-60:40, and described surfactant is Span-80 and Tween-80, described Span-80's and Tween-80
Weight ratio is 3:7～5:5；
Its preparation process is:
(1) oligofructose, stachyose, preservative and acidic flavoring agent are dissolved in distilled water, stirring and dissolving, then mix with glycerol
Uniformly；
(2) under stirring, it is slowly added into Tween-80 toward step (1) gained solution, obtains clear transparent solutions；
(3) Camellia oil and Span-80 mixing and stirring, yellow clear transparent solutions is obtained；
(4) mechanical agitation is slowly added to step (3) gained solution in step (2) gained solution, finally gives clear
Orange-yellow microemulsion.
Further: described preservative is sorbic acid and potassium salt thereof.
Microemulsion (Microemulsion, ME) described in the present invention is the Thermodynamically stable that two kinds of mutual insoluble liq are formed
, isotropic, appearance transparent or translucent dispersion.It is typically oil, water, emulsifying agent and co-emulsifier to spontaneously form
Isotropism, the thermodynamics and kinetics stabilising system of clear.It is widely used in daily-use chemical industry, tertiary oil recovery,
The aspects such as enzyme catalysis.Owing to microemulsion is in addition to the general aspects with Emulsion, also have stable, clear, particle diameter are little
Advantage, has obtained increasing attention in the field such as pharmaceutical preparation and clinic the most in recent years.Microemulsion divides according to structure
For oil-in-water type, water-in-oil type and bicontinuous.Water oil-packaging type micro-emulsion can Solubilization of Water soluble drug, improve water soluble drug
Stability and bioavailability.
A kind of tetrose that stachyose of the present invention is naturally-occurring, molecular formula is C24H42O21, it is that one can be notable
Promote the functional oligose of bacillus bifidus propagation. as the one of bifidus factor, stachyose is to the bifid in human gastrointestinal tract
The profitable strain such as bacillus, lactobacillus has extremely significantly proliferation function, can improve rapidly environment in human body alimentary canal, regulate micro-
Ecological balance.Promoting to be formed probiotics dominant bacteria status in digestive tract, suppression aerogenesis produces the corruption such as acid clostridium
The production of bacterium, additionally produces a large amount of biological active substances, regulating intestinal canal pH value, kills pathogenic bacterium, checks spoilage product and generates, presses down
Make endogenous carcinogenic generation and absorption.
Oligofructose is a kind of water soluble dietary fiber, and long-term taking can reduce serum cholesterol, improve lipid metabolism,
Confirm through animal and human experimentation.Oligofructose has following physiological function: utilized by probioticss such as bacillus bifiduss, the most only increases
Grow 10 ~ 100 times, time bacillus bifidus (pathogenic bacterium), there is effect of two-ways regulation.After human body takes in oligofructose, internal useful
Flora bifidobacteria can suppress the growth and breeding such as external source pathogenic bacterium and enteral intrinsic Putrefying bacteria such as Salmonella, reduces intestinal
The growth of interior corrupt substance and accumulation, promote intestinal peristalsis promoting, prevent constipation and diarrhoea.Low calorie value, owing to oligofructose can not
Directly digested and assimilated by human body, can only be absorbed by intestinal bacteria, therefore its calorific value is low, be also a kind of for diabetics
Good sweeting agent.
Glycerol, is commonly called as glycerol, is without the sweet clear and bright thick liquid of color and taste, odorless, has warm sweet taste.Not only can serve as helping table
Face activating agent, medically, glycerol is emollient laxative.Can lubricate and stimulate intestinal wall, soften stool so that it is be prone to discharge, effect
Gentle.Make suppository, took effect in 30 minutes.Make enema, existing lubrication, rectum intestinal wall, reflexive ground can be stimulated again
Cause defecation.It is applicable to the treatment of constipation, is specially adapted to child and elderly and infirm.
The present invention compared with prior art, has the advantages that
1, this microemulsion has Camellia oil, stachyose and oligofructose, to the bacillus bifidus in human gastrointestinal tract, lactic acid due to compounding
The profitable strains such as bacillus have extremely significantly proliferation function, can improve rapidly environment in human body alimentary canal, and microecosystem regulation balances
And reduce the growth of enteral corrupt substance and accumulation, promote intestinal peristalsis promoting, prevent constipation and diarrhoea, owing to oligofructose can not be by
Human body is directly digested and assimilated, and can only be absorbed by intestinal bacteria, therefore its calorific value is low, is a kind of good for diabetics
Sweeting agent.
2, due to the fact that the most sugary, and due to integration of edible and medicinal herbs, this product is the most effective, and has no side effect,
Pure green, is the preferable the intestines and stomach coordinating of diabetes patient, Constipation functional food, and taste of the present invention is good, pleasing appearance.
Detailed description of the invention
Below in conjunction with instantiation, the invention will be further described:
Embodiment 1:
Use the raw material of following metering: Camellia oil 20 kilograms, surfactant Span-80 12 kilograms, surfactant Tween-
80 28 kilograms, oligofructose 3.0 kilograms, 0.1 kilogram of stachyose, sorbic acid 0.05 kilogram, acidic flavoring agent 0.5 kilogram, glycerol
11.35 kilograms, distilled water 25 kilograms；
Preparation process is:
(1) oligofructose, stachyose, preservative and acidic flavoring agent are dissolved in distilled water, stirring and dissolving, then mix with glycerol
Uniformly；
(2) under stirring, it is slowly added into Tween-80 toward step (1) gained solution, obtains clear transparent solutions；
(3) Camellia oil and Span-80 mixing and stirring, yellow clear transparent solutions is obtained；
(4) mechanical agitation is slowly added to step (3) gained solution in step (2) gained solution, finally gives clear
Orange-yellow microemulsion.
Embodiment 2:
Use the raw material of following metering: Camellia oil 30 kilograms, surfactant Span-80 15 kilograms, surfactant Tween-
80 15 kilograms, oligofructose 0.1 kilogram, 1 kilogram of stachyose, preservative sorbic acid 0.03 kilogram, acidic flavoring agent 0.1 kilogram, third
Triol 22.77 kilograms, distilled water 16 kilograms；
Preparation process is:
(1) oligofructose, stachyose, preservative and acidic flavoring agent are dissolved in distilled water, stirring and dissolving, then mix with glycerol
Uniformly；
(2) under stirring, it is slowly added into Tween-80 toward step (1) gained solution, obtains clear transparent solutions；
(3) Camellia oil and Span-80 mixing and stirring, yellow clear transparent solutions is obtained；
(4) mechanical agitation is slowly added to step (3) gained solution in step (2) gained solution, finally gives clear
Orange-yellow microemulsion.
Embodiment 3:
Use the raw material of following metering: Camellia oil 25 kilograms, surfactant Span-80 16 kilograms, surfactant Tween-
80 24 kilograms, oligofructose 1.5 kilograms, 0.5 kilogram of stachyose, preservative sorbic acid 0.03 kilogram, acidic flavoring agent 0.75 kilogram,
Glycerol 16.22 kilograms, distilled water 16 kilograms；
Preparation process is:
(1) oligofructose, stachyose, preservative and acidic flavoring agent are dissolved in distilled water, stirring and dissolving, then mix with glycerol
Uniformly；
(2) under stirring, it is slowly added into Tween-80 toward step (1) gained solution, obtains clear transparent solutions；
(3) Camellia oil and Span-80 mixing and stirring, yellow clear transparent solutions is obtained；
(4) mechanical agitation is slowly added to step (3) gained solution in step (2) gained solution, finally gives clear
Orange-yellow microemulsion.
Clinical trial:
(1) testing crew physical data
Select case 60 example, male 33 examples, female 27 example, age 31-70 year, 46.2 years old mean age, course of disease 2-27
Year, average 11.2.
(2) diagnostic criteria
Observe case diabetes diagnostic criterion and all meet the diagnostic criteria that WHO proposes 1997, and have row in various degree
Just difficulty, constipation with dry stool, defecation feels and the clinical manifestation such as infrequent defecation time length not to the utmost, gets rid of the serious heart, brain, kidney concurrent
Disease, colon, rectum organic disease, Metcalf improvement simplification technical measurement Colonic transit time are got rid of in x line barium enema
(CTT) upper limits of normal is all exceeded 56 hours.
(3) test method
Morning every day on an empty stomach and respectively takes embodiment 1 prepared microemulsion evening once, and each 20mL, serveing on 15 days is one
The course for the treatment of, each course for the treatment of, every three days, takes three courses for the treatment of continuously.Be careful in one's diet conditioning simultaneously, avoids maror, forms timing stool
Custom.
(4) treatment criterion
Cure: every 1-2 days defecations 1 time, just matter turns profit, solution just time unobstructed, short-term is without recurrence.
Effective: stool time interval relatively treats front shortening, and subjective symptoms alleviates, and needs once in a while to take cathartic medicine；
Invalid: symptom is not improved or recurs during treating and even increases the weight of.
(5) therapeutic outcome
The present invention treats 60 examples, cures 16 examples, effective 40 examples, invalid 4 examples, cure rate 26.6%, effective percentage
66.7%, inefficiency 7%, total effective rate 93%.
Claims (5)
1. the microemulsion being applicable to diabetes patient's Constipation, it is characterised in that include the raw material of following weight percents:
Camellia oil 20-30%, surfactant 30-40%, oligofructose 0.1-3.0%, stachyose 0.1-1.0%, preservative
The weight of 0.01-0.05%, acidic flavoring agent 0.5-1.0%, cosurfactant glycerol and distilled water surplus, glycerol and distilled water
Amount ratio is 30:70-60:40.
The microemulsion being applicable to diabetes patient's Constipation the most according to claim 1, it is characterised in that: live in described surface
Property agent is Span-80 and Tween-80, and the weight ratio of described Span-80 and Tween-80 is 3:7～5:5.
The microemulsion being applicable to diabetes patient's Constipation the most according to claim 1, it is characterised in that: described preservative
For sorbic acid and potassium salt thereof.
4. the preparation method of the microemulsion being applicable to diabetes patient's Constipation, it is characterised in that use following weight percent
The raw material of ratio:
Camellia oil 20-30%, surfactant 30-40%, oligofructose 0.1-3.0%, stachyose 0.1-1.0%, preservative
The weight of 0.01-0.05%, acidic flavoring agent 0.5-1.0%, cosurfactant glycerol and distilled water surplus, glycerol and distilled water
Amount ratio is 30:70-60:40, and described surfactant is Span-80 and Tween-80, described Span-80's and Tween-80
Weight ratio is 3:7～5:5；
Its preparation process is:
(1) oligofructose, stachyose, preservative and acidic flavoring agent are dissolved in distilled water, stirring and dissolving, then mix with glycerol
Uniformly；
(2) under stirring, it is slowly added into Tween-80 toward step (1) gained solution, obtains clear transparent solutions；
(3) Camellia oil and Span-80 mixing and stirring, yellow clear transparent solutions is obtained；
(4) mechanical agitation adds step (3) gained solution in step (2) gained solution, finally give the orange of clear
Yellow microemulsion.
The preparation method of the microemulsion being applicable to diabetes patient's Constipation the most according to claim 4, it is characterised in that:
Described preservative is sorbic acid and potassium salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610264495.8A CN105901712A (en) | 2016-04-26 | 2016-04-26 | Microemulsion for preventing constipation of diabetics and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610264495.8A CN105901712A (en) | 2016-04-26 | 2016-04-26 | Microemulsion for preventing constipation of diabetics and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105901712A true CN105901712A (en) | 2016-08-31 |
Family
ID=56752047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610264495.8A Pending CN105901712A (en) | 2016-04-26 | 2016-04-26 | Microemulsion for preventing constipation of diabetics and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105901712A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108576820A (en) * | 2018-03-30 | 2018-09-28 | 广州富诺营养科技有限公司 | A kind of algae oil DHA composite particles and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103283866A (en) * | 2013-06-09 | 2013-09-11 | 浙江大学 | Camellia oil microemulsion and preparation method thereof |
| CN103478295A (en) * | 2013-09-30 | 2014-01-01 | 管天球 | Calcium-supplement and health-care grape seed oil |
| CN104840612A (en) * | 2015-05-31 | 2015-08-19 | 安庆市孝柱食品科技有限公司 | Low-sugar tea oil emulsion |
-
2016
- 2016-04-26 CN CN201610264495.8A patent/CN105901712A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103283866A (en) * | 2013-06-09 | 2013-09-11 | 浙江大学 | Camellia oil microemulsion and preparation method thereof |
| CN103478295A (en) * | 2013-09-30 | 2014-01-01 | 管天球 | Calcium-supplement and health-care grape seed oil |
| CN104840612A (en) * | 2015-05-31 | 2015-08-19 | 安庆市孝柱食品科技有限公司 | Low-sugar tea oil emulsion |
Non-Patent Citations (1)
| Title |
|---|
| 潘道东等: "《功能性食品添加剂》", 31 January 2006, 中国轻工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108576820A (en) * | 2018-03-30 | 2018-09-28 | 广州富诺营养科技有限公司 | A kind of algae oil DHA composite particles and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107343657B (en) | Ketogenic diet formula powder | |
| DE60210604T3 (en) | POLYMER-CONTROLLED INDUCED VISCOSES BRAZING SYSTEM AND ITS USES | |
| CN101744170B (en) | Tartary buckwheat eight ingredient porridge suitable for patients with diabetes and preparing method thereof | |
| CN102224891B (en) | Sugar alcohol honey apple jam and preparation method thereof | |
| CN103238897A (en) | Composite plant solid drink suitable for diabetic patients | |
| CN102613566B (en) | Health care product for relaxing bowel and preparation method of heath care product | |
| CN103445170B (en) | Spleen-tonifying and stomach-nourishing powder | |
| CN112369606A (en) | Low-carbon ketogenic food and preparation method thereof | |
| CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
| CN102461587A (en) | Selenium-rich folium mori black grain flour food for preventing and treating diabetes | |
| CN104413120A (en) | Black garlic and millet biscuit and preparation method thereof | |
| CN103404778A (en) | Tartary buckwheat noodle | |
| CN105707378A (en) | Black-highland barley coffee with effect of slimming | |
| CN107307033A (en) | A kind of biscuit with the aid digestion effect of strengthening the spleen and stomach and preparation method thereof | |
| CN104489472B (en) | It is a kind of to be used to improve indigestion, the food of diarrhoea | |
| CN105901712A (en) | Microemulsion for preventing constipation of diabetics and preparation method thereof | |
| WO2005056022A1 (en) | Enteropathy ameliorating composition | |
| CN106470691A (en) | Comprise cinnamic aldehyde and the compositionss of zinc and the using method of such composition | |
| CN105901713A (en) | Constipation preventing microemulsion and preparation method thereof | |
| CN106474413B (en) | It is a kind of for treat the weakness of the spleen and the stomach children, eating accumulation, anorexia Orally administered composition | |
| DE69232126T3 (en) | Ingestible preparations containing water-soluble, highly viscous cellulose ethers | |
| CN108618020A (en) | A kind of relax bowel improves the dietary food product of constipation | |
| CN104415215A (en) | Application of black garlic powder to adjustment of intestinal flora of animal | |
| CN111068027B (en) | Traditional Chinese medicine composition for regulating and treating yang deficiency and sub-health, and preparation method and application thereof | |
| CN104116999A (en) | Preparation for improving intestinal microbial environment and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160831 |
|
| RJ01 | Rejection of invention patent application after publication |